This week I’m writing from the 2016 BIO International Convention where over 15,000 biotechnology and pharma leaders have come together to learn and network. The convention includes a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels,... read more
With the number of patents being invalidated under 35 U.S.C. § 101 on Motions to Dismiss after Mayo and Alice, there’s a fair question – what happened to the presumption of validity that is owed to a patent?  Seemingly, it still exists. 35 U.S.C. § 282 states:A patent shall be presumed... read more
The intellectual property protection of 3D organs may eventually prove harder than the science itself. For example, are 3D organs “human organisms” under Section 33(a) of the AIA? Are 3D organs and/or bioprinting patent-eligible subject matter under Supreme Court interpretations of 35 U.S.C. § 101... read more
The first FDA approved 3D printed pharmaceutical is an epilepsy drug produced by Aprecia Pharmaceuticals Company (“Aprecia”). In its press release, Aprecia noted that the epilepsy drug, called Spritam® levetiracetam, has been approved for oral use to treat partial onset seizures, myoclonic seizures... read more
Today the USPTO announced the launch of an interesting voluntary pilot program called the Patents for Humanity Program. The program is an awards competition for patent owners and licensees who apply their patented technologies to address humanitarian needs.Submissions will be accepted between March... read more
Via the Chicago Tribune, a quick update on the progress of efforts at the USPTO to increase the speed of processing patents on nanotechnology.  The conclusion in a nutshell: not much has happened. Alan Gotcher, president and chief executive of Altair Nanotechnologies Inc. based in Reno,... read more
I am somewhat behind in my journal reading, so while this may be somewhat older news it was something that I wanted to share with the blog-o-sphere. According to C&EN News (Chemical and Engineering News – November 7, 2005 issue), Standford University’s chemistry department... read more
from Bio-IT World: CAMBIA, an independent, nonprofit institute based in Canberra, Australia, has set up BIOS (Biological Innovation for Open Society), which aims to extend the concepts of open source to biotechnology and other forms of innovation in biology. Last week CAMBIA introduced under an... read more
According to a Washington Post article, a human-animal hybrid is not patentable. Apparently a human hybrid is too close to a human. However, since the famous case of Diamond v. Chakrabarty, patents have been awarded to bacteria, yeast, and even animals. Chakrabarty's most famous quote on... read more
According to the Report on, Federal Court Invalidates Patent on Merck's No. 2 Drug: The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated the patent for the once-a-week version of Merck's Fosamax, which dominates the market for osteoporosis drugs. Under the... read more
Russ over at Anything Under the Sun Made By Man recently posted Silver Lining to Fee Increases. With the new legislation on fees for patents, comes some structural change. Now you can save 50% on filing fees by using electronic filing. While it requires learning the software, it may actually... read more
As many of you already know, the fee increase for the USPTO is official. As of last Wednesday, fees have increased again. That's two fee increases in a little over 2 months. President Bush signed the Consolidated Appropriations Act for 2005 on December 8, 2004, effective immediately. Unfortunately... read more
Oklahoma Inventors Congress has a link to an article discussing the various aspects of intellectual property associated with ordinary businesses. The article is on (free registration required). It is directed to U.K. readers, so don't take every detail as absolute truth.... read more
As PHOSITA previously reported, the USPTO has instituted a new classification for nanotechnology,  Class 977–nanotechnology, to provides for disclosures: related to research and technology development at the atomic, molecular or macromolecular levels, in the length of scale of... read more
Outsourcing is a highly contentious and potentially cost-saving measure that is constantly in the news these days.  Sending work off-shore (or, more specifically, outside the U.S.) provides a company the benefits of oftentimes highly educated labor forces that can complete ... read more